articleThe Lancet OncologyMar 20, 2020GREEN OA

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

GKGhassan K. Abou‐AlfaVSVaibhav SahaiAHAntoine HollebecqueGMGina M. VaccaroDMDavide Melisi

Memorial Sloan Kettering Cancer Center · Cornell University · +18 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,560
total citations
FWCI
79.35
Percentile
100%
References
35
Citations per year

Authors

19

Topics & keywords

Topics
Keywords
  • Medicine
  • Clinical endpoint
  • Fibroblast growth factor receptor
  • Internal medicine
  • Fibroblast growth factor
  • Phases of clinical research
  • Cancer
  • Toxicity
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding